Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 4/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19361232 | 0.86 | CYP2C9 (0.40) | GABRA2GABRB2CYP19A1 | |
| SCHEMBL14212090 | 0.86 | GABRA2 (0.38) | GABRA2GABRB2CYP19A1CYP4F2CYP4A11 | |
| SCHEMBL18401359 | 0.85 | CYP19A1 (0.34) | GABRA2GABRB2CYP19A1 | |
| SCHEMBL15222209 | 0.84 | GABRA2 (0.45) | GABRA2GABRB2CYP19A1 | |
| SCHEMBL14212094 | 0.82 | NOTUM (0.41) | GABRA2GABRB2CYP19A1CYP4F2CYP4A11 | |
| SCHEMBL25734935 | 0.82 | GABRA2 (0.32) | GABRA2GABRB2CYP19A1 | |
| SCHEMBL11954946 | 0.82 | NOTUM (0.43) | — | |
| SCHEMBL20812235 | 0.79 | NOTUM (0.44) | GABRA2GABRB2CYP19A1CYP4F2CYP4A11 | |
| SCHEMBL25588830 | 0.79 | DDX3X (0.41) | GABRA2GABRB2CYP19A1CYP4F2CYP4A11 | |
| SCHEMBL18767836 | 0.79 | GABRA2 (0.49) | GABRA2GABRB2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266326-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9550000-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20140328756-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266326-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | GABRA2 3201/4885GABRB2 3915/4885CYP19A1 2566/4885 |
| US-20140328756-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | GABRA2 3201/4885GABRB2 3915/4885CYP19A1 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.